Saxonov Serge 4

What Happened

• Serge Saxonov, CEO of 10x Genomics, reported an open-market sale of 5,000 shares on April 14, 2026. The weighted average sale price was $24.56, with trade prices ranging from $24.49 to $24.70, for total proceeds of approximately $122,784. This was a sale (not a purchase), and such transactions are commonly routine dispositions.

Key Details

• Transaction date: 2026-04-14 (reported on Form 4 filed 2026-04-16)
• Transaction type/code: Open-market sale (S)
• Shares sold: 5,000; weighted average price: $24.56; price range: $24.49–$24.70; proceeds ≈ $122,784
• Ownership after transaction: Not specified in the provided filing excerpt
• Notable footnotes:
  • F1: Sale executed pursuant to a Rule 10b5-1 trading plan adopted Nov 29, 2025
  • F2: Multiple trades; Reporting Person can provide breakdown of shares sold at each price on request
  • F3–F5: Some shares referenced are held in trusts (Andromeda Trust, Y/S Descendants' Trust, Y/S Pot Trust) for which Saxonov serves as trustee
• Timeliness: Filed within the typical two-business-day window (not indicated as late)

Context

• The sale was executed under a pre-established 10b5-1 plan, which is designed to allow insiders to sell shares according to a predetermined schedule and reduce concerns about trading on inside information. Sales are generally less informative than purchases about an insider’s view of the company; this entry documents a routine disposition rather than an acquisition.